Rifampicin-Based Tuberculosis Treatment and Interactions

Introduction to Rifampicin and Moxifloxacin

• The American Thoracic Society guidelines suggest that rifampicin remains the cornerstone of effective TB therapy, and moxifloxacin-containing shortened regimens have demonstrated significantly higher relapse rates 1
• Rifampicin is irreplaceable as the backbone of first-line TB therapy due to its unique sterilizing activity against dormant bacilli, as recommended by the American Thoracic Society 1

Recommended Management Strategy

• The American Thoracic Society recommends continuing rifampicin-based ATT as the standard of care for drug-susceptible TB, with a strength of evidence based on clinical guidelines 1, 2

When Moxifloxacin IS Appropriate in TB Treatment

• The ATS/CDC/ERS/IDSA guidelines suggest adding a later-generation fluoroquinolone, such as moxifloxacin, to a 6-month regimen of rifampin, ethambutol, and pyrazinamide for isoniazid-resistant TB, with moderate-strength evidence 3, 4
• Moxifloxacin can be used as part of a non-hepatotoxic regimen when INH, rifampicin, and pyrazinamide all cause hepatitis, until liver enzymes normalize, as recommended by the American Thoracic Society 1
• Moxifloxacin becomes a core component of MDR-TB regimens, according to the American Thoracic Society guidelines 3

Critical Pitfalls to Avoid

• The American Thoracic Society warns against compromising TB treatment efficacy by removing rifampicin simply to accommodate voriconazole, as TB treatment failure and relapse carry significant morbidity and mortality, with high-strength evidence 1